Sirolimus in Refractory Cronkhite-Canada Syndrome and Focus on Standard Treatment

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cronkhite-Canada syndrome is a rare syndrome consisting of extensive gastrointestinal polyposis and ectodermal changes including cutaneous hyperpigmentation, alopecia, and onychodystrophy. We report the case of a 45-year-old Caucasian male patient who failed multiple treatments over 2 years including steroids, azathioprine, adalimumab, and cyclosporine. He had recurrent and prolonged hospitalizations because of diarrhea, abdominal pain, weight loss, and malnutrition. Sirolimus was initiated with a significant clinical and endoscopic benefit apparent within, respectively, 2 and 8 weeks. An ongoing remission was achieved and maintained for over 6 months after prednisone tapering. We review the current evidence on treatment of Cronkhite-Canada syndrome and suggest the incorporation of sirolimus in that algorithm.

Cite

CITATION STYLE

APA

Langevin, C., Chapdelaine, H., Picard, J. M., Poitras, P., & Leduc, R. (2018). Sirolimus in Refractory Cronkhite-Canada Syndrome and Focus on Standard Treatment. Journal of Investigative Medicine High Impact Case Reports, 6. https://doi.org/10.1177/2324709618765893

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free